0.71
price down icon0.67%   -0.0048
after-market アフターアワーズ: .72 0.01 +1.41%
loading
前日終値:
$0.7148
開ける:
$0.7076
24時間の取引高:
3.04M
Relative Volume:
1.23
時価総額:
$119.48M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.4863
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
+10.59%
1か月 パフォーマンス:
+14.94%
6か月 パフォーマンス:
-44.53%
1年 パフォーマンス:
-59.43%
1日の値動き範囲:
Value
$0.6597
$0.7366
1週間の範囲:
Value
$0.57
$0.7366
52週間の値動き範囲:
Value
$0.432
$1.855

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1157)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
0.71 119.48M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
432.00 115.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
574.16 60.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
542.47 37.56B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.86 35.18B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
224.73 26.10B 3.81B -644.79M -669.77M -6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
10:33 AM

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

10:33 AM
pulisher
May 12, 2025

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks

May 12, 2025
pulisher
May 12, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 12, 2025
pulisher
May 12, 2025

Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com

May 12, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st

May 09, 2025
pulisher
May 09, 2025

NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView

May 09, 2025
pulisher
May 09, 2025

BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com

May 09, 2025
pulisher
May 09, 2025

Nektar: Q1 Earnings Snapshot - The Washington Post

May 09, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timelines | NKTR Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses Estimate, Revenue Falls Short at $10.5 Million - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Reports First Quarter 2025 Financial Results - PR Newswire

May 08, 2025
pulisher
May 08, 2025

Unmet Needs in Atopic Dermatitis and the Impact of Roflumilast Cream, with Raj Chovatiya, MD, PhD - HCPLive

May 08, 2025
pulisher
May 08, 2025

Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com

May 08, 2025
pulisher
May 07, 2025

Nektar Therapeutics's Earnings: A Preview - Nasdaq

May 07, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 01, 2025

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal

May 01, 2025
pulisher
May 01, 2025

Nektar to Announce Financial Results for the First Quarter on Th - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets | NKTR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Upcoming Nektar Q1 2025 Earnings Call: CEO Howard Robin to Present Financial Results May 8 - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

May 01, 2025
pulisher
Apr 16, 2025

Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com

Apr 16, 2025
pulisher
Apr 16, 2025

Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN

Apr 16, 2025
pulisher
Apr 13, 2025

Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus

Apr 13, 2025
pulisher
Apr 12, 2025

Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq

Apr 12, 2025
pulisher
Apr 12, 2025

Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

Sector Update: Health Care - TradingView

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider

Apr 11, 2025
pulisher
Apr 11, 2025

Jefferies Upgrades Nektar (NKTR) with Optimistic Outlook on Phase 2b Study | NKTR Stock News - GuruFocus

Apr 11, 2025

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wilson Mark Andrew
Chief Legal Officer
Feb 19 '25
Sale
1.01
11,040
11,150
324,292
ROBIN HOWARD W
President & CEO
Feb 19 '25
Sale
1.01
23,774
24,012
1,086,901
$65.71
price down icon 3.01%
$19.31
price down icon 3.11%
$32.82
price down icon 1.59%
$24.61
price down icon 2.57%
$94.50
price down icon 2.85%
biotechnology ONC
$224.73
price down icon 3.65%
大文字化:     |  ボリューム (24 時間):